Dengue Vaccines Market Growth, Regional Analysis, Trends and Forecast 2022-2031Posted by Ganesh Shinde on December 22nd, 2022 ![]() Increasing prevalence of dengue fever throughout the Asia-Pacific region has propelled the demand for effectual medicines and vaccines to overcome this viral disease. While some pharmaceutical companies are focusing on development of a cure to dengue, the rate of dengue in Asia-Pacific region in expanding robustly. According a report published by Future Market Insights (FMI), Asia-Pacific region will dominate in the Dengue Vaccines Market during the forecast period (2017-2027). The region is estimated to procure largest revenue share with expansion at 17.4% CAGR throughout the assessment period. Geographic Overview Latin America is likely to remain the second largest market for dengue vaccines and it will procure valuation nearly US$ 290 Mn by the end of forecast period. The report also forecasts that more and more pharmaceutical companies will be partaking in the expansion of dengue vaccines market in foreseeable period. A French drugmaker, Sanofi S.A. is actively participated in the market currently, while medicines are being formulated by leading players such as GlaxoSmithKline plc, Vabiotech, Merck & Co. Inc., Butantan Institute, Panacea Biotech Ltd, Takeda Pharmaceutical Company Limited, and Biological E. Limited. According to the report, government institutes will continue to be the largest end-users of dengue vaccines. Dengue vaccine sales across government institutes will generate nearly US0 million in revenue by the end of 2027. Furthermore, hospitals will maintain their dominance, with double-digit CAGRs throughout the forecast period. Sales of the sole vaccine, Dengvaxia, manufactured by Sanofi, are currently driving market growth. Furthermore, the factors influencing the market growth profiled in the report are discussed below. Key Highlights of Dengue Vaccines Market Report
Overall, the global dengue vaccines market, which is currently valued nearly US$ 250 Mn, will increase rapidly to reach over US$ 1,250 Mn in terms of revenues, by the end of 2027. Get More Insights@ https://www.futuremarketinsights.com/reports/dengue-vaccines-market Like it? Share it!More by this author |